Evaluation of Ranibizumab in Proliferative Diabetic Retinopathy (PDR) Requiring Vitrectomy

Status unconfirmed · Phase 3

Conditions studied: Proliferative Diabetic Retinopathy

In brief

Evaluation of ranibizumab on the ease and procedure and complication in proliferative diabetic retinopathy (PDR) requiring vitrectomy.

Key facts

Study ID

NCT00516464

Run by

Retina Associates, Kansas City

People needed

40

Starts

2007-08-01

Expected to finish

2008-08-01

Last updated by the study team

2007-08-15

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Ability to provide written informed consent and comply with study assessments for the full duration of the study
• Age > 20 years
• Best corrected visual acuity of 20/40 to 20/800 in the study eye
• Very servere nonproliferative diabetic retinopathy (ETDRS level 53E) OR moderate proliferative diabetic retinopathy (ETDRS level 65)
• Visual reduction attributable to diabetic vitreous hemorrhage or diabetic macular edema
• Candidate for vitrectomy procedure

You may not qualify if…

• Pregnancy (positive Pregnancy test) or lactation
• Premenopausal women not using adequate contraception. The following are considered effective means of contraception: surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an IUD, or contraceptive hormone implant or patch.
• Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated.
• Participation in another simultaneous medical investigation or trial.
• Visual impairment attributable to causes other than diabetic macular edema or diabetic vitreous hemorrhage.
• Use of intraocular or periocular corticosteroids within 6 months.
• History of panretinal photocoagulation
• History of macular laser photocoagulation
• History of pars plana vitrectomy
• Prior or concomitant treatment with ranibizumab, bevacizumab, or pegaptanib sodium, either as part of an investigational study or as an off-label medication.
• Current treatment of a systemic infection

Where it is running

• Retina Associates, PA — Shawnee Mission, Kansas, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.